Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VTK-125
- Development stage
- Preclinical
- Lead developer
- Vitarka Therapeutics
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
01
Overview
VTK-125 is a pan-RAS protein degrader being developed by Vitarka Therapeutics for the treatment of Glioblastoma Multiforme (GBM). The drug is specifically engineered to be blood-brain barrier (BBB) permeable, allowing for effective delivery to the central nervous system (CNS). As a pan-RAS degrader, VTK-125 is designed to target and eliminate multiple isoforms of the RAS protein family, including KRAS, HRAS, and NRAS, which are key drivers in oncogenic signaling and tumor progression in glioblastoma. The program is currently in the preclinical stage of development.
- Other names
- Pan-RAS Degrader
Beyond the preview
Go deeper on VTK-125.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VTK-125.